Melatonin in autism spectrum disorders: a systematic review and meta-analysis
- PMID: 21518346
- DOI: 10.1111/j.1469-8749.2011.03980.x
Melatonin in autism spectrum disorders: a systematic review and meta-analysis
Abstract
Aim: The aim of this study was to investigate melatonin-related findings in autism spectrum disorders (ASD), including autistic disorder, Asperger syndrome, Rett syndrome, and pervasive developmental disorders, not otherwise specified.
Method: Comprehensive searches were conducted in the PubMed, Google Scholar, CINAHL, EMBASE, Scopus, and ERIC databases from their inception to October 2010. Two reviewers independently assessed 35 studies that met the inclusion criteria. Of these, meta-analysis was performed on five randomized double-blind, placebo-controlled studies, and the quality of these trials was assessed using the Downs and Black checklist.
Results: Nine studies measured melatonin or melatonin metabolites in ASD and all reported at least one abnormality, including an abnormal melatonin circadian rhythm in four studies, below average physiological levels of melatonin and/or melatonin derivates in seven studies, and a positive correlation between these levels and autistic behaviors in four studies. Five studies reported gene abnormalities that could contribute to decreased melatonin production or adversely affect melatonin receptor function in a small percentage of children with ASD. Six studies reported improved daytime behavior with melatonin use. Eighteen studies on melatonin treatment in ASD were identified; these studies reported improvements in sleep duration, sleep onset latency, and night-time awakenings. Five of these studies were randomized double-blind, placebo-controlled crossover studies; two of the studies contained blended samples of children with ASD and other developmental disorders, but only data for children with ASD were used in the meta-analysis. The meta-analysis found significant improvements with large effect sizes in sleep duration (73 min compared with baseline, Hedge's g 1.97 [95% confidence interval {CI} CI 1.10-2.84], Glass's Δ 1.54 [95% CI 0.64-2.44]; 44 min compared with placebo, Hedge's g 1.07 [95% CI 0.49-1.65], Glass's Δ 0.93 [95% CI 0.33-1.53]) and sleep onset latency (66 min compared with baseline, Hedge's g-2.42 [95% CI -1.67 to -3.17], Glass's Δ-2.18 [95% CI -1.58 to -2.76]; 39 min compared with placebo, Hedge's g-2.46 [95% CI -1.96 to -2.98], Glass's Δ-1.28 [95% CI -0.67 to -1.89]) but not in night-time awakenings. The effect size varied significantly across studies but funnel plots did not indicate publication bias. The reported side effects of melatonin were minimal to none. Some studies were affected by limitations, including small sample sizes and variability in the protocols that measured changes in sleep parameters.
Interpretation: Melatonin administration in ASD is associated with improved sleep parameters, better daytime behavior, and minimal side effects. Additional studies of melatonin would be helpful to confirm and expand on these findings.
© The Authors. Developmental Medicine & Child Neurology © 2011 Mac Keith Press.
Comment in
-
Meta-analysing the effectiveness of melatonin for sleep-disturbed individuals with autism spectrum conditions: should Rett syndrome be included?Dev Med Child Neurol. 2011 Nov;53(11):1063; author reply 1064. doi: 10.1111/j.1469-8749.2011.04071.x. Epub 2011 Aug 12. Dev Med Child Neurol. 2011. PMID: 21838821 No abstract available.
Similar articles
-
[Therapeutic approaches for sleep and rhythms disorders in children with ASD].Encephale. 2022 Jun;48(3):294-303. doi: 10.1016/j.encep.2021.08.005. Epub 2022 Feb 1. Encephale. 2022. PMID: 35120753 Clinical Trial. French.
-
Sleep Disorders in Children and Adolescents with Autism Spectrum Disorder: Diagnosis, Epidemiology, and Management.CNS Drugs. 2020 Apr;34(4):415-423. doi: 10.1007/s40263-020-00710-y. CNS Drugs. 2020. PMID: 32112261 Review.
-
Melatonin in autism spectrum disorders.Curr Clin Pharmacol. 2014;9(4):326-34. doi: 10.2174/15748847113086660072. Curr Clin Pharmacol. 2014. PMID: 24050742 Review.
-
The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome.J Clin Sleep Med. 2009 Apr 15;5(2):145-50. J Clin Sleep Med. 2009. PMID: 19968048 Free PMC article. Clinical Trial.
-
Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems.Child Care Health Dev. 2006 Sep;32(5):585-9. doi: 10.1111/j.1365-2214.2006.00616.x. Child Care Health Dev. 2006. PMID: 16919138 Clinical Trial.
Cited by
-
Sleep disturbance in Angelman syndrome patients.Orphanet J Rare Dis. 2024 Apr 5;19(1):146. doi: 10.1186/s13023-024-03154-5. Orphanet J Rare Dis. 2024. PMID: 38580983 Free PMC article. Review.
-
Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease.Antioxidants (Basel). 2023 Dec 23;13(1):34. doi: 10.3390/antiox13010034. Antioxidants (Basel). 2023. PMID: 38247459 Free PMC article. Review.
-
Factors contributing to U.S. parents' decisions to administer melatonin to children.Sleep Med. 2024 Feb;114:49-54. doi: 10.1016/j.sleep.2023.12.018. Epub 2023 Dec 22. Sleep Med. 2024. PMID: 38154149
-
On-demand electrically controlled melatonin release from PEDOT/SNP composite improves quality of chronic neural recording.Front Bioeng Biotechnol. 2023 Nov 15;11:1284927. doi: 10.3389/fbioe.2023.1284927. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 38033812 Free PMC article.
-
Association of early bedtime at 3 years of age with higher academic performance and better non-cognitive skills in elementary school.Sci Rep. 2023 Nov 27;13(1):20926. doi: 10.1038/s41598-023-48280-5. Sci Rep. 2023. PMID: 38017093 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous